GlaxoSmithKline plc (GSK) – Growth in Specialty Medicine

in , , on September 12, 2022

This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for insights on any specific sector/industry and market recommendations.

GlaxoSmithKline plc (GSK)

In this quarter, the company also completed the acquisition of Sierra Oncology and announced the proposed acquisition of Affinivax. Both of these transactions are excellent examples of strategic business development to develop a strong portfolio of innovative vaccines and specialty medicines.



– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance


Stock Price Performance

Crispidea Coverage

No of Pages : 32

Release Information

  • Price


  • Released

    September 12, 2022

  • Last Updated

    September 15, 2022